Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)

202010 citationsJournal Articlegold Open Access

Authors

Tadaaki Yamada · Kyoto Prefectural University of Medicine

Junji Uchino · Kyoto Prefectural University of Medicine

Yusuke Chihara · Kyoto Prefectural University of Medicine

Takayuki Shimamoto · Kyoto Prefectural University of Medicine

Masahiro Iwasaku · Kyoto Prefectural University of Medicine

Nobuyo Tamiya · Kyoto Prefectural University of Medicine

Yoshiko Kaneko

Abstract

We are conducting an intervention study to investigate the safety and efficacy of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy.

Topics & Keywords

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Therapeutic Advances in Medical Oncology

Volume 12, pp. 1758835920927841-1758835920927841

DOI: 10.1177/1758835920927841

Field-Weighted Citation Impact: 1.14